CAT extends DRC offer again

Cambridge Antibody Tech Group PLC
28 March 2002

02/CAT/15

Not for release in Australia, Japan and the Republic of Ireland

FOR IMMEDIATE RELEASE

22.00 GMT 17.00 EST Wednesday 27 March 2002

For Further Information Contact:

Cambridge Antibody Technology              Weber Shandwick Square Mile (Europe)

Tel: [phone]                  Tel: [phone]

John Aston, Finance Director               Kevin Smith

Rowena Gardner, Head of Corporate          Graham Herring
Communications
                                           BMC Communications/The Trout Group (USA)

                                           Tel: [phone]

                                           Brad Miles, ext 17 (media)

                                           Brandon Lewis, ext.15 (investors)



CAMBRIDGE ANTIBODY TECHNOLOGY FURTHER EXTENDS OFFER FOR DRUG ROYALTY CORPORATION
                                TO 26 APRIL 2002

Melbourn, UK and Toronto, Canada... Cambridge Antibody Technology Group plc
("CAT") (LSE: CAT; NASDAQ: CATG) announced today that it has extended its offer,
through its wholly-owned subsidiary 3982904 Canada Inc., to acquire all of the
outstanding common shares of Drug Royalty Corporation Inc. ("DRC") (TSE: DRI) to
9.00 pm (EST) on Friday 26 April 2002. A formal notice of the extension of the
offer will be mailed as soon as is practicable.

                                -ENDS-


                      This information is provided by RNS
            The company news service from the London Stock Exchange